Hormone Replacement Therapy (HRT) Market, By Replacement Therapy (Estrogen, Human Growth Hormone, Testosterone and Thyroid), By Route of Administration, By Disease, and Geography (NA, EU, APAC, and RoW) Analysis, Share, Trends, Size, & Forecast From 2014 2025
REPORT HIGHLIGHT
The Hormone Replacement Therapy (HRT) market is estimated to represent a global market of USD 15.8 billion by 2017 with growth rate of 7.5%.
Market Dynamics
Menopause is a natural and inevitable event, defined as the final menstrual period. It requires a retrospective clinical diagnosis with ethnic and regional variations. Hormone replacement therapies (HRT) such as systemic estrogen (skin patch, gel, or cream) are considered to be the most effective treatment option in the treatment of menopausal night sweats and hot flashes. These therapies also ease vaginal symptoms of menopause such as itching, burning, and dryness. Due to this fact, women undergoing these therapies has increased considerably over the past few years.
As per the Rose Research Survey (April 2014), women accepting HT therapy has increased considerably, from 4.5 million in 2005 to around 5.0 million in 2014. In addition to this, the growth of this market is attributed to the rise in a number of women in menopausal age coupled with growing patient awareness. For example, according to the International Menopause Society, thousands of women reach menopause experience every day. On another hand, the high cost of therapies coupled with the high risk of adverse reactions posing a potential threat to this industry. For example, as per the study published in PLOS One journal in 2014, testosterone therapy in cardiac patients considerably increase the risk of heart attack.
Replacement Therapy Takeaway
In terms of replacement therapy, the market is categorized as Estrogen, Human Growth Hormone, Testosterone and Thyroid. Estrogen replacement therapy recorded USD 9.58 billion and is expected to soar owing to the approval of new products by the United States Food and Drug Association under this category. Some of the recommended estrogen doses for women with Primary Ovarian Insufficiency (POI) are 1.25 mg conjugated equine estrogen (CEE), 17b-estradiol 2 mg/day, and transdermal estradiol 75–100 mg/day.
Furthermore, Climara, Estradot, Divigel, Elestrin, and EstroGel are some of the commercially available transdermal estrogen products in the U.S. and Canada market by various manufacturers. On contrary, thyroid replacement therapy is considered to be the lowest revenue generating segment and is also pegged to register slowest growth rate i.e. 6.9% in terms of value. Levothyroxine (generic form of thyroxine) is a most commonly prescribed thyroid hormone replacement drug across the globe.
Route of Administration Takeaway
Route of administration is divided into Parenteral, Oral, Transdermal, and other. Among which, the parenteral segment recorded the highest share of the global market owing to its associated benefits. For example, parenteral administration of estrogen protect against the effects of andropause and reduce toxicity compared to the oral administration. The disease segment is divided into Male hypogonadism, Menopause, Hypothyroidism, Growth hormone deficiency, and others. Hypothyroidism is the lowest revenue generating segment, captured less than 15% share throughout the forecast period.
Regional Takeaway
Regionally, the market is divided into North America, Europe, Asia Pacific and Rest of the World. Of these, North America captured the highest share, 41.67% of the total market. Drugs such as Premarin, AndroGel, and Levothyroxine have been recorded to gain the maximum prescription within this region. However, Asia Pacific region represents one of the fastest growing regions, enjoying an annual average growth rate over 9.0%. Rising awareness levels coupled with increasing focus of healthcare and government on eradication of hormonal deficiencies are likely to establish a healthy platform for the industry growth in this region.
Key Vendor Takeaway
Companies such as Novo Nordisk, Amgen, Inc., Abbott, Eli Lily and Genentech are covered under research study. The industry experiences a high level of competition. In such fragmented landscape, key players are actively engaged in strategic collaborations to expand their market presence. For instance, in February 2015, Mylan Laboratories signed an agreement for the acquisition of Famy Care.
This acquisition has helped the company to increase its female health product portfolio inclusive of production of hormone replacement drugs, Intra-Uterine Devices (IUD), and contraceptives. Likewise, in December 2014, Pfizer collaborated with OPKO Health. As per the agreement, OPKO would be developing and marketing long-acting human growth hormone (hGH-CTP) (PF-06836922), whereas Pfizer would take care of the post-market studies and development costs.
The market size and forecast for each segment and sub-segments has been considered as below:
- Historical Year – 2014 & 2016
- Base Year – 2017
- Estimated Year – 2018
- Projected Year – 2025
TARGET AUDIENCE
- Traders, Distributors, and Suppliers
- Manufacturers
- Hospitals
- Government and Regional Agencies and Research Organizations
- Consultants
- Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY REPLACEMENT THERAPY
- Estrogen
- Human Growth Hormone
- Testosterone
- Thyroid
MARKET, BY ROUTE OF ADMINISTRATION
- Parenteral
- Oral
- Transdermal
- Other
MARKET, BY DISEASE
- Male Hypogonadism
- Menopause
- Hypothyroidism
- Growth Hormone Deficiency
- Others
MARKET, BY REGION
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- Rest of Europe
- Asia Pacific
- India
- China
- Rest of APAC
- Rest of the World
- Middle East and Africa
- Latin America
TABLE OF CONTENT
1. HORMONE REPLACEMENT THERAPY (HRT) MARKET OVERVIEW
1.1. Study Scope
1.2. Assumption and Methodology
2. EXECUTIVE SUMMARY
2.1. Key Market Facts
2.2. Geographical Scenario
2.3. Companies in the Market
3. HORMONE REPLACEMENT THERAPY (HRT) KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. HORMONE REPLACEMENT THERAPY (HRT) INDUSTRY STUDY
4.1. Porter’s Analysis
4.2. Market Attractiveness Analysis
4.3. Regulatory Framework Analysis
5. HORMONE REPLACEMENT THERAPY (HRT) MARKET LANDSCAPE
5.1. Market Share Analysis
6. HORMONE REPLACEMENT THERAPY (HRT) MARKET – BY REPLACEMENT THERAPY
6.1. Overview
6.2. Estrogen
6.2.1. Overview
6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.3. Human Growth Hormone
6.3.1. Overview
6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.4. Testosterone
6.4.1. Overview
6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.5. Thyroid
6.5.1. Overview
6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7. HORMONE REPLACEMENT THERAPY (HRT) MARKET – BY ROUTE OF ADMINISTRATION
7.1. Overview
7.2. Parenteral
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.3. Oral
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.4. Transdermal
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.5. Other
7.5.1. Overview
7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8. HORMONE REPLACEMENT THERAPY (HRT) MARKET – BY DISEASE
8.1. Overview
8.2. Male Hypogonadism
8.2.1. Overview
8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.3. Menopause
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.4. Hypothyroidism
8.4.1. Overview
8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.5. Growth Hormone Deficiency
8.5.1. Overview
8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.6. Others
8.6.1. Overview
8.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9. HORMONE REPLACEMENT THERAPY (HRT) MARKET– BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. Overview
9.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9.2.3. U.S.
9.2.3.1. Overview
9.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9.2.4. Canada
9.2.4.1. Overview
9.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9.3. Europe
9.3.1. Overview
9.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9.3.3. France
9.3.3.1. Overview
9.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9.3.4. Germany
9.3.4.1. Overview
9.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9.3.5. Rest of Europe
9.3.5.1. Overview
9.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9.4. Asia Pacific (APAC)
9.4.1. Overview
9.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9.4.3. China
9.4.3.1. Overview
9.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9.4.4. India
9.4.4.1. Overview
9.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9.4.5. Rest of APAC
9.4.5.1. Overview
9.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9.5. Rest of the World
9.5.1. Overview
9.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9.5.3. Latin America
9.5.3.1. Overview
9.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9.5.4. Middle East and Africa
9.5.4.1. Overview
9.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
10. KEY VENDOR ANALYSIS
10.1. Novo Nordisk
10.1.1. Company Overview
10.1.2. SWOT Analysis
10.1.3. Key Developments
10.2. Amgen, Inc.
10.2.1. Company Overview
10.2.2. SWOT Analysis
10.2.3. Key Developments
10.3. Abbott
10.3.1. Company Overview
10.3.2. SWOT Analysis
10.3.3. Key Developments
10.4. Eli Lily & Company
10.4.1. Company Overview
10.4.2. SWOT Analysis
10.4.3. Key Developments
10.5. Genentech
10.5.1. Company Overview
10.5.2. SWOT Analysis
10.5.3. Key Developments
*Client can request additional company profiling as per specific requirements
11. 360 DEGREE ANALYSTVIEW
12. APPENDIX
12.1. Research Methodology
12.2. Abbreviations
12.3. Disclaimer
12.4. Contact Us
List of Tables
Table 1 List of Acronyms
Table 2 Key Market Facts, 2014 – 2025
Table 3 Market Drivers: Impact Analysis
Table 4 Market Restraint: Impact Analysis
Table 5 Market Opportunity: Impact Analysis
Table 6 PEST Analysis
Table 7 Porter’s Five Forces Analysis
Table 8 Company Market Share Analysis
Table 9 Global Hormone Replacement Therapy (HRT) Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
Table 10 Hormone Replacement Therapy (HRT) Market, by Replacement Therapy, 2014 – 2025 (USD Billion)
Table 11 Hormone Replacement Therapy (HRT) Market, by Route of Administration, 2014 – 2025 (USD Billion)
Table 12 Hormone Replacement Therapy (HRT) Market, by Disease, 2014 – 2025 (USD Billion)
Table 13 Hormone Replacement Therapy (HRT) Market, by Geography, 2014 – 2025 (USD Billion)
Table 14 North America Hormone Replacement Therapy (HRT) Market, 2014 – 2025 (USD Billion)
Table 15 U.S. Hormone Replacement Therapy (HRT) Market, 2014 – 2025 (USD Billion)
Table 16 Canada Hormone Replacement Therapy (HRT) Market, 2014 – 2025 (USD Billion)
Table 17 Europe Hormone Replacement Therapy (HRT) Market, 2014 – 2025 (USD Billion)
Table 18 France Hormone Replacement Therapy (HRT) Market, 2014 – 2025 (USD Billion)
Table 19 Germany Hormone Replacement Therapy (HRT) Market, 2014 – 2025 (USD Billion)
Table 20 Asia Pacific Hormone Replacement Therapy (HRT) Market, 2014 – 2025 (USD Billion)
Table 21 China Hormone Replacement Therapy (HRT) Market, 2014 – 2025 (USD Billion)
Table 22 India Hormone Replacement Therapy (HRT) Market, 2014 – 2025 (USD Billion)
Table 23 Latin America Hormone Replacement Therapy (HRT) Market, 2014 – 2025 (USD Billion)
Table 24 MEA Hormone Replacement Therapy (HRT) Market, 2014 – 2025 (USD Billion)
List of Figures
Figure 1 Research Methodology
Figure 2 Research Process Flow Chart
Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)
Figure 4 Regulatory Framework Analysis
Figure 5 Hormone Replacement Therapy (HRT) Market, by Replacement Therapy, 2014 – 2025 (USD Billion)
Figure 5 Hormone Replacement Therapy (HRT) Market, by Route of Administration, 2014 – 2025 (USD Billion)
Figure 5 Hormone Replacement Therapy (HRT) Market, by Disease, 2014 – 2025 (USD Billion)
Figure 6 Hormone Replacement Therapy (HRT) Market, by Geography, 2014 – 2025 (USD Billion)
